



National Center for Advancing Translational Sciences

Joint Meeting of the National Center for Advancing Translational Sciences (NCATS) Advisory Council (19th) and

Cures Acceleration Network (CAN) Review Board (24th)

Building 31C, 6th Floor, Conference Room 6, NIH Campus, Bethesda, Maryland Open Session of the meeting will be webcast. To view, please go to <u>NIH Videocast</u>.

8:30 a.m. Call to Order, Open Session > Christopher P. Austin, M.D., Director, NCATS; Chairperson, NCATS Advisory Council > G. Lynn Marks, M.D., Senior Research & Development (R&D) Advisor, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS); Chairperson, CAN Review Board Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings Approval of Minutes from May 2018 Joint Meeting > Anna L. Ramsey-Ewing, Ph.D., Director, Office of Grants Management and Scientific Review, NCATS; Executive Secretary, NCATS Advisory Council and CAN Review Board 8:35 a.m. Director's Report > Christopher P. Austin, M.D., Director, NCATS Discussion BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory > Bobbie Ann Mount, Ph.D., Program Officer, Orige Development Program, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening of Biofabricated 3-D Disease Tissue Models > Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose for Drug Screening > Dobrila D. Rudnicki, Ph.D., Program Manager, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" >	September 27, 2018 Agenda				
 G. Lynn Marks, M.D., Senior Research & Development (R&D) Advisor, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS); Chairperson, CAN Review Board Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings Approval of Minutes from May 2018 Joint Meeting Anna L. Ramsey-Ewing, Ph.D., Director, Office of Grants Management and Scientific Review, NCATS; Executive Secretary, NCATS Advisory Council and CAN Review Board 8:35 a.m. Director's Report Christopher P. Austin, M.D., Director, NCATS Discussion 9:45 a.m. BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Manager, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS 	8:30 a.m.	8:30 a.m. Call to Order, Open Session			
Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS); Chairperson, CAN Review BoardConfirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings Approval of Minutes from May 2018 Joint Meeting 		Christopher P. Austin, M.D., Director, NCATS; Chairperson, NCATS Advisory Council			
Approval of Minutes from May 2018 Joint Meeting> Anna L. Ramsey-Ewing, Ph.D., Director, Office of Grants Management and Scientific Review, NCATS; Executive Secretary, NCATS Advisory Council and CAN Review Board8:35 a.m.Director's Report> Christopher P. Austin, M.D., Director, NCATSDiscussion9:45 a.m.BREAK10:00 a.m.Clearance of ConceptsDrug Development Collaboratory> Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATSDrug Screening of Biofabricated 3-D Disease Tissue Models> Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATSBiofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening> Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATSBiofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening> Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS"Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases> Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS"HEAL Pain Effectiveness Research Network (HEAL Pain-ERN)> Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS		Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS);			
 Anna L. Ramsey-Ewing, Ph.D., Director, Office of Grants Management and Scientific Review, NCATS; Executive Secretary, NCATS Advisory Council and CAN Review Board 8:35 a.m. Director's Report Christopher P. Austin, M.D., Director, NCATS Discussion 9:45 a.m. BREAK Clearance of Concepts Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose for Drug Screening Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS 		Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings			
NCATS; Executive Secretary, NCATS Advisory Council and CAN Review Board 8:35 a.m. Director's Report > Christopher P. Austin, M.D., Director, NCATS Discussion 9:45 a.m. BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory > Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models > Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening > Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" > Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases > Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) > Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate		Approval of Minutes from May 2018 Joint Meeting			
 Christopher P. Austin, M.D., Director, NCATS Discussion 9:45 a.m. BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Manager, Office of Special Initiatives, NCATS Itisue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS 					
Discussion 9:45 a.m. BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory > Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models > Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening > Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" > Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases > Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) > Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate	8:35 a.m.	Director's Report			
9:45 a.m. BREAK 10:00 a.m. Clearance of Concepts Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS 		Christopher P. Austin, M.D., Director, NCATS			
 10:00 a.m. Clearance of Concepts Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS 		Discussion			
 Drug Development Collaboratory Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 	9:45 a.m.	BREAK			
 Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Program, NCATS Drug Screening of Biofabricated 3-D Disease Tissue Models Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 	10:00 a.m.	a.m. Clearance of Concepts			
Drug Screening of Biofabricated 3-D Disease Tissue Models ▶ Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening ▶ Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" ▶ Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases ▶ Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) ▶ Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate					
 Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
 Biofabricated 3-D Tissue Models of Nociception, Addiction and Overdose for Drug Screening Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
 Dobrila D. Rudnicki, Ph.D., Program Officer, Office of Special Initiatives, NCATS Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
 Tissue Chips to Model Nociception, Addiction and Overdose: "Tissue Chips to HEAL" Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 		• • • • •			
 Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS "Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
 Lucie Low, Ph.D., Scientific Program Manager, Office of Special Initiatives, NCATS HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
 HEAL Pain Effectiveness Research Network (HEAL Pain-ERN) Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 		"Clinical Trials on a Chip": Tissue Chips to Inform Clinical Trials for Rare Diseases			
 Jane C. Atkinson, D.D.S., Director, Trial Innovation Network, Division of Clinical Innovation, NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate 					
NCATS CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate		· · ·			
		CTSA Program: Competitive Supplement Applications to Develop, Demonstrate and Disseminate			
Translational Science Advances		Translational Science Advances			
Michael G. Kurilla, M.D., Ph.D., Director, Division of Clinical Innovation, NCATS		Michael G. Kurilla, M.D., Ph.D., Director, Division of Clinical Innovation, NCATS			

Noon	LUNCH		
1:00 p.m.	When Does a Patient Become a Research Participant?		
	Follow-up to May 2018 Advisory Council Discussion		
	Valery M. Gordon, Ph.D., M.P.H., Senior Advisor for Human Subjects Protections, Division of Clinical Innovation, NCATS		
	Discussion		
1:30 p.m.	CTSA Program Update: Integrating Novel Informatics Tools and Community Engagement to		
	Increase Participant Recruitment and Retention		
	Patricia Jones, Dr.P.H., M.P.H., Lead, Common Metrics Initiative Program, Division of Clinical Innovation, NCATS		
	Paul Harris, Ph.D., Professor of Biomedical Informatics, Research Professor of Biomedical Engineering, Department of Biomedical Informatics, Vanderbilt University		
	Consuelo H. Wilkins, M.D., MSCI, Executive Director, Meharry-Vanderbilt Alliance,		
	Associate Professor of Medicine, Vanderbilt University Medical Center and Meharry Medical College		
3:00 р.т.	Adjourn, Open Session		
	Christopher P. Austin, M.D., Director, NCATS; Chairperson, NCATS Advisory Council		
	 G. Lynn Marks, M.D., Senior R&D Advisor, BARDA, ASPR, HHS; Chairperson, CAN Review Board 		
3:15 p.m.	Closed Session		

Future Advisory Council and CAN Review Board Joint Meetings					
<u>201</u>	.9	<u>2020</u>			
Janua	iry 10	January 16			
May 2	16	May 14			
Septe	mber 19	September 17			
Future CAN Review Board (only) Meetings (virtual)					
<u>2018</u>	<u>2019</u>	<u>2020</u>			
December 14	December 13	December 11			